EP3863615A4 - Verfahren zur behandlung von krebsen mit soliden tumoren unter verwendung von illudinen und biomarkern - Google Patents

Verfahren zur behandlung von krebsen mit soliden tumoren unter verwendung von illudinen und biomarkern Download PDF

Info

Publication number
EP3863615A4
EP3863615A4 EP19872565.7A EP19872565A EP3863615A4 EP 3863615 A4 EP3863615 A4 EP 3863615A4 EP 19872565 A EP19872565 A EP 19872565A EP 3863615 A4 EP3863615 A4 EP 3863615A4
Authority
EP
European Patent Office
Prior art keywords
illudins
biomarkers
methods
solid tumor
treating solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19872565.7A
Other languages
English (en)
French (fr)
Other versions
EP3863615A1 (de
Inventor
Aditya KULKAMI
Yuvanesh VEDARAJU
Umesh KATHAD
Arun ASAITHAMBI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lantern Pharma Inc
Original Assignee
Lantern Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lantern Pharma Inc filed Critical Lantern Pharma Inc
Publication of EP3863615A1 publication Critical patent/EP3863615A1/de
Publication of EP3863615A4 publication Critical patent/EP3863615A4/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP19872565.7A 2018-10-14 2019-10-14 Verfahren zur behandlung von krebsen mit soliden tumoren unter verwendung von illudinen und biomarkern Pending EP3863615A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862745382P 2018-10-14 2018-10-14
PCT/US2019/056039 WO2020081414A1 (en) 2018-10-14 2019-10-14 Methods for the treatment of solid tumor cancers using illudins and biomarkers

Publications (2)

Publication Number Publication Date
EP3863615A1 EP3863615A1 (de) 2021-08-18
EP3863615A4 true EP3863615A4 (de) 2022-08-03

Family

ID=70284107

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19872565.7A Pending EP3863615A4 (de) 2018-10-14 2019-10-14 Verfahren zur behandlung von krebsen mit soliden tumoren unter verwendung von illudinen und biomarkern

Country Status (6)

Country Link
EP (1) EP3863615A4 (de)
JP (2) JP2022513349A (de)
CN (1) CN113194934B (de)
AU (2) AU2019361781A1 (de)
CA (1) CA3116552A1 (de)
WO (1) WO2020081414A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4146181A4 (de) * 2020-05-08 2024-10-09 Lantern Pharma Inc. Verfahren zur behandlung von bauchspeicheldrüsenkrebs
JP2023551709A (ja) * 2020-11-18 2023-12-12 ランタン ファルマ インコーポレイテッド がん薬物感受性決定マーカー
CN116847834A (zh) * 2021-01-08 2023-10-03 蓝腾制药公司 使用隐陡头菌素或羟基脲甲基酰基富烯治疗脑转移瘤和cns转移瘤
JP2024528725A (ja) * 2021-07-29 2024-07-30 ランタン ファルマ インコーポレイテッド Ｐａｒｐ阻害剤及びアシルフルベンの併用によるがんの治療
KR20240073856A (ko) * 2021-07-29 2024-05-27 랜턴 파마 인코포레이티드 스피로노락톤 및 아실풀벤의 조합을 이용한 암의 치료
EP4554683A2 (de) * 2022-07-15 2025-05-21 Lantern Pharma Inc. Verfahren zur behandlung von brustkrebs und parp-resistentem brustkrebs
CN116287275B (zh) * 2023-04-10 2024-04-05 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） Ptgr1作为cdk4/6抑制剂与二甲双胍联合用药指导标志物的应用
CN117233391A (zh) * 2023-08-28 2023-12-15 南方医科大学南方医院 一种用于预测胃癌免疫治疗和/或化疗疗效的生物标志物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007019308A2 (en) * 2005-08-03 2007-02-15 The Regents Of The University Of California Illudin analogs useful as anticancer agents
US9725769B1 (en) * 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
WO2018170230A1 (en) * 2017-03-15 2018-09-20 Memorial Sloan Kettering Cancer Center Diagnosis & treatment of ercc3-mutant cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8039210B2 (en) * 2004-05-14 2011-10-18 The Johns Hopkins University Protein tyrosine phosphatase mutations in cancers
JP5429735B2 (ja) * 2009-03-25 2014-02-26 富士フイルム株式会社 食道癌の検出方法及び抑制剤
AU2013202104B2 (en) * 2012-01-13 2015-11-26 Celgene Corporation Biomarkers for the treatment of hepatocellular carcinoma
US10285955B2 (en) * 2014-04-10 2019-05-14 Af Chemicals, Llc Affinity medicant conjugate
WO2015157578A2 (en) * 2014-04-10 2015-10-15 Af Chemicals, Llc Affinity medicant conjugates
EP3161489A4 (de) * 2014-06-26 2018-04-18 Institute for Systems Biology Marker und therapeutische indikatoren für glioblastoma multiforme (gbm)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007019308A2 (en) * 2005-08-03 2007-02-15 The Regents Of The University Of California Illudin analogs useful as anticancer agents
US9725769B1 (en) * 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
WO2018170230A1 (en) * 2017-03-15 2018-09-20 Memorial Sloan Kettering Cancer Center Diagnosis & treatment of ercc3-mutant cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MARINA TANASOVA ET AL: "Chemistry and Biology of Acylfulvenes: Sesquiterpene-Derived Antitumor Agents", CHEMICAL REVIEWS, vol. 112, no. 6, 6 April 2012 (2012-04-06), US, pages 3578 - 3610, XP055665990, ISSN: 0009-2665, DOI: 10.1021/cr2001367 *
See also references of WO2020081414A1 *
STAAKE MICHAEL D ET AL: "Hydroxyurea derivatives of irofulven with improved antitumor efficacy", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 26, no. 7, 13 February 2016 (2016-02-13), pages 1836 - 1838, XP029453930, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2016.02.028 *

Also Published As

Publication number Publication date
CN113194934B (zh) 2025-02-25
WO2020081414A1 (en) 2020-04-23
AU2019361781A1 (en) 2021-06-03
JP2025111438A (ja) 2025-07-30
JP2022513349A (ja) 2022-02-07
EP3863615A1 (de) 2021-08-18
CN113194934A (zh) 2021-07-30
AU2025234250A1 (en) 2025-10-09
CA3116552A1 (en) 2020-04-23

Similar Documents

Publication Publication Date Title
EP3863615A4 (de) Verfahren zur behandlung von krebsen mit soliden tumoren unter verwendung von illudinen und biomarkern
EP3947715A4 (de) Verfahren und zusammensetzungen zur behandlung von krebs
EP3894392A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs
EP3775167A4 (de) Verfahren zur krebsbehandlung unter verwendung von tumorantigenspezifischen t-zellen
MA42136A (fr) Anticorps anti-cd38 pour le traitement de l&#39;amyloïdose à chaînes légères et d&#39;autres tumeurs malignes hématologiques positives à cd38
EP3610269A4 (de) Verfahren und vorrichtung zur bestimmung der markierungszahl während der charakterisierung von proben
MA47208A (fr) Procédés de traitement du cancer à l&#39;aide d&#39;anticorps anti-pd-1
EP3801563A4 (de) Materialien und verfahren zur behandlung von krebs
EP3506944A4 (de) Zusammensetzungen und verfahren zur behandlung von tumor-suppressor-defizientem krebs
EP3828289A4 (de) Verfahren und kit zur identifizierung eines magenkrebszustands
EP3775171A4 (de) Verfahren zur behandlung von minimalem restkrebs
EP3874068A4 (de) Verfahren zur diagnose und behandlung von krebs mit nicht-menschlichen nukleinsäuren
EP3427051A4 (de) Protein- und autoantikörper-biomarker zur diagnose und behandlung von lungenkrebs
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
EP3833340A4 (de) Zusammensetzungen und verfahren zur behandlung von presbyopie
EP3792363A4 (de) Verfahren und kit zur identifizierung eines lungenkrebszustands
EP3792362A4 (de) Verfahren und kit zur identifizierung des zustands von kolorektalkrebs
EP3781584A4 (de) 4&#39;-thio-nukleotid- und -nukleosid-prodrugs zur behandlung von krebs
MA55143A (fr) Composés aryl-aniline et hétéroaryl-aniline pour le traitement de cancers de la peau
EP3937939A4 (de) Immunmodulatorische kombinationen und verfahren zur behandlung von krebs
EP3894561A4 (de) Verfahren zur behandlung von krebs
MA45865A (fr) Procédés de détection et de traitement d&#39;une tumeur exprimant pt346 pdk1
EP3968987A4 (de) Verfahren und materialien zur behandlung von krebs
EP3873205A4 (de) Materialien und verfahren zur behandlung von krebs
EP3773625A4 (de) Verfahren und materialien zur behandlung von krebs

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210514

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40060097

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20220630

RIC1 Information provided on ipc code assigned before grant

Ipc: C12Q 1/6886 20180101ALI20220627BHEP

Ipc: A61P 35/00 20060101ALI20220627BHEP

Ipc: A61K 31/17 20060101ALI20220627BHEP

Ipc: C12Q 1/686 20180101ALI20220627BHEP

Ipc: C07C 239/14 20060101ALI20220627BHEP

Ipc: A61K 31/122 20060101AFI20220627BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240710